RYBREVANT® (amivantamab-vmjw) + chemo delivers long median OS in EGFR exon 20 insertion mutation-positive NSCLC September 16, 2026
Enhertu demonstrated a median PFS of 14.3 months IN 1L HER2-mutant advanced NSCLC in DESTINY-Lung04 Ph 3 trial September 16, 2026
NEJM Publishes Ph 1/2 Clinical Data on RASONQUE™ (daraxonrasib) in Metastatic NSCLC September 9, 2026
Ivonescimab Meets OS Key Secondary Endpoint in Interim Analysis of Ph 3 HARMONi-2 Study, Demonstrating Statistically Significant Benefit Versus Pembrolizumab in 1L PD-L1-Positive NSCLC September 9, 2026
FDA Fast Track Designation for BH-30643 for the Treatment of Advanced EGFR C797S-positive NSCLC August 25, 2026
Zipalertinib + Chemo Meet Primary PFS Endpoint in Planned Interim Analysis of Ph 3 REZILIENT3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC August 20, 2026
Enhertu demonstrated statistically significant and clinically meaningful PFS improvement in HER2-mutant NSCLC in DESTINY-Lung04 Ph 3 trial August 20, 2026
IDMC recommends discontinuing the eVOLVE-Lung02 Ph 3 trial of volrustomig + chemo in 1L metastatic NSCLC with PD-L1 <50% August 20, 2026
Final ASTRUM-002 Analysis Shows Survival Benefit with Hetronifly in Advanced non squamous NSCLC After Four Years of Follow-Up August 20, 2026
Ivonescimab + Chemo Approved in China by NMPA for 1L Treatment of Patients with Squamous NSCLC August 20, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
Ivonescimab + Chemo Shows Consistent, Favorable OS Results in Western and Asian Patients in Updated Analysis from Global Ph 3 HARMONi Study July 28, 2026
Supplemental Application accepted for Toripalimab + Chemo as Perioperative Treatment for Resectable Stage II-III NSCLC July 28, 2026
Ph 3 Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as 1L PD-L1-Neg Non-Squamous NSCLC Met Primary Endpoint July 22, 2026
Strong Initial Efficacy Data Reported in 3L NSCLC from Ph 2 THIO-101 Part C Expansion Trial July 15, 2026
Results from ELEVATE study of postoperative adjuvant ensartinib in stage IB–IIIB (T3N2M0) ALK-positive NSCLC published in NEJM July 15, 2026
Clinical results of Ph 1b/2 trial of ifebemtinib + garsorasib in 1L KRASG12C-mutant NSCLC published in The Lancet Respiratory Medicine July 15, 2026
Global Data for Pumitamig Shows Encouraging Efficacy in NSCLC Patients in ROSETTA Lung-02 Trial July 15, 2026
Ph 3 AURORA Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced NSCLC Patients with Inadequate Response to Immune Checkpoint Inhibitors initiated July 7, 2026
Divarasib shows superiority in head-to-head Ph 3 trial against sotorasib or adagrasib in NSCLC July 7, 2026
FAILED TRIAL: Ph 3 SigVie-002/Be6A Lung-01 trial of sigvotatug vedotin in 2L+ NSCLC did not show a statistically significant OS improvement vs docetaxel June 30, 2026
